Solid Biosciences: Duchenne Community Update

Solid Biosciences Logo

Solid Bioscience has announced the acquisition of AavantiBio, the pause of their first-generation gene transfer therapy candidate SGT-001, and the prioritization of SGT-003, their next-generation adeno-associated virus (AAV) gene transfer therapy candidate.

Continue reading